Previous close | 1,756.20 |
Open | 1,749.20 |
Bid | 1,725.40 x 0 |
Ask | 1,725.40 x 0 |
Day's range | 1,712.00 - 1,756.80 |
52-week range | 1,215.83 - 1,817.00 |
Volume | |
Avg. volume | 10,749,254 |
Market cap | 88.034B |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | 17.16 |
EPS (TTM) | 100.90 |
Earnings date | 27 Jul 2022 |
Forward dividend & yield | 0.75 (4.24%) |
Ex-dividend date | 19 May 2022 |
1y target est | 1,798.36 |
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.